Leap <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces $58.9 Million Private Placement Led by Winklevoss Capital to Launch <a href="https://laohu8.com/S/DAAQU">Digital Asset</a> Treasury <a href="https://laohu8.com/S/MSTR">Strategy</a>
Leap Therapeutics Inc. (Nasdaq: LPTX), a biotechnology company specializing in targeted and immuno-oncology therapies, has announced a $58.88 million private placement led by Winklevoss Capital. The financing involves the sale of approximately 95.8 million shares of common stock or pre-funded warrants, along with additional warrants to purchase about 71.9 million shares at an exercise price of $0.5335 per share. The aggregate exercise price per unit is set at $0.61439. The funds raised will support Leap's newly initiated digital asset treasury strategy. Parcrest is serving as the placement agent, with Morgan, Lewis & Bockius LLP advising Leap and Cooley LLP advising Winklevoss Capital. The closing of the private placement is expected soon, pending customary closing conditions. Leap plans to provide further updates on its treasury activities in the near term.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE90771) on October 06, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。